Recent Quotes

My Watchlist

Top Indices

Articles published by Ironwood Pharmaceuticals, Inc.

< Previous 1 2 3 Next >

Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call

October 20, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation

September 06, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference

September 01, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand

August 04, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call

July 21, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022

May 25, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022

May 09, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance

May 05, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call

April 21, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021

February 17, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call

February 03, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance

January 10, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 05, 2022

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer

December 01, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update

November 04, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.

November 04, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021

October 25, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call

October 21, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences

September 02, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label

August 26, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance

August 05, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer

August 03, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call

July 22, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

June 16, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Announces Leadership Updates

June 07, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength

May 26, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW)

May 24, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021

May 17, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program

May 06, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports First Quarter 2021 Results

May 06, 2021

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.